Literature DB >> 21990303

Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.

Dima M Qato1, G Caleb Alexander.   

Abstract

Mesh：

Year:  2011        PMID： 21990303     DOI： 10.1001/jama.2011.1457

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

1.  Quality of Reporting on the Evaluation of Risk Minimization Programs: A Systematic Review.

Authors:  Andrea M Russell; Elaine H Morrato; Rebecca M Lovett; Meredith Y Smith
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

Review 2.  FDA drug safety communications: a narrative review and clinical considerations for older adults.

Authors:  Zachary A Marcum; Joseph P Vande Griend; Sunny A Linnebur
Journal:  Am J Geriatr Pharmacother       Date:  2012-06-08

3.  Academic centers play a vital role in the study of drug safety and effectiveness.

Authors:  Jingwen Tan; G Caleb Alexander; Jodi B Segal
Journal:  Clin Ther       Date:  2013-03-22       Impact factor: 3.393

4.  Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients.

Authors:  Sheriza N Baksh; Walid F Gellad; G Caleb Alexander
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

5.  Inappropriate Fentanyl Prescribing Among Nursing Home Residents in the United States.

Authors:  Kevin M Fain; Carlos Castillo-Salgado; David D Dore; Jodi B Segal; Andrew R Zullo; G Caleb Alexander
Journal:  J Am Med Dir Assoc       Date:  2016-10-06       Impact factor: 4.669

6.  End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.

Authors:  Shamia Hoque; Brian J Chen; Martin W Schoen; Kenneth R Carson; Jesse Keller; Bartlett J Witherspoon; Kevin B Knopf; Y Tony Yang; Benjamin Schooley; Chadi Nabhan; Oliver Sartor; Paul R Yarnold; Paul Ray; Laura Bobolts; William J Hrushesky; Michael Dickson; Charles L Bennett
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.